DOCSLIB.ORG

Leukemia Cells Are Sensitized to Temozolomide, Carmustine and Melphalan by the Inhibition of O6‑Methylguanine‑DNA Methyltransferase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Leukemia Cells Are Sensitized to Temozolomide, Carmustine and Melphalan by the Inhibition of O6‑Methylguanine‑DNA Methyltransferase ONCOLOGY LETTERS 10: 845-849, 2015 Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6‑methylguanine‑DNA methyltransferase HAJIME ARAI, TAKAHIRO YAMAUCHI, KANAKO UZUI and TAKANORI UEDA Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui 910-1193, Japan Received August 8, 2014; Accepted April 13, 2015 DOI: 10.3892/ol.2015.3307 Abstract. The cytotoxicity of the monofunctional alkylator, Introduction temozolomide (TMZ), is known to be mediated by mismatch repair (MMR) triggered by O6-alkylguanine. By contrast, the Alkylating agents comprise a major class of chemo- cytotoxicity of bifunctional alkylators, including carmustine therapeutic agents, widely used in various types of cancer, (BCNU) and melphalan (MEL), depends on interstrand cross- including leukemia (1,2). There are two types of alkyl- links formed through O6-alkylguanine, which is repaired by ating agents: monofunctional and bifunctional agents. nucleotide excision repair and recombination. O6-alkylguanine Bifunctional alkylating agents include cyclophosphamide, is removed by O6-methylguanine-DNA methyltransferase ifosfamide, melphalan (MEL) and carmustine (BCNU; (MGMT). The aim of the present study was to evaluate the cyto- also known as 1,3-bis(2-chloroethyl)-1-nitrosourea). toxicity of TMZ, BCNU and MEL in two different leukemic Monofunctional agents include temozolomide [TMZ; cell lines (HL-60 and MOLT-4) in the context of DNA repair. also known as 3,4-dihydro-3-methyl-4-oxoimidazo The transcript levels of MGMT, ERCC1, hMLH1 and hMSH2 (5,1-d)-as-tetrazine-8-carboxamide] and dacarbazine (1-3). were determined using reverse transcription-quantitative Alkylating agents form a variety of DNA adducts in polymerase chain reaction. In addition, the proliferation was cancer cells, including mono-adducts on N1-alkylguanine, measured using the trypan blue exclusion assay. Drug sensi- N3-alkyladenine, N7-alkylguanine or O6-alkylguanine, and tivity was found to vary between the two cell lines. Treatment di-adducts between or within DNA strands (1-4). Bifunctional of the cells with TMZ, BCNU or MEL in combination with alkylating agents result in cytotoxicity due to the production O6-benzylguanine, an MGMT inhibitor, was demonstrated of interstrand crosslinks, which are formed through the to sensitize the two cell lines to these agents. However, the intermediate production of O6-alkylguanine (5,6). These extent of sensitization was not found to be correlated with the crosslinks are repaired through nucleotide excision repair expression levels of MGMT transcripts. Furthermore, the drug (NER) and recombination. By contrast, monofunctional sensitivity was also not associated with the transcript levels agents generate persistent O6-methylguanine adducts that of ERCC1, hMLH1 and hMSH2. Thus, leukemic cells were initiate futile cycling of the DNA mismatch repair (MMR) sensitized to alkylating agents by the inhibition of MGMT. pathway, which causes DNA double-strand breaks (7-10). Intact MMR is required for the exertion of the cytotox- icity of monofunctional agents. The DNA repair enzyme, O6-methylguanine-DNA methyltransferase (MGMT), repairs O6-alkylguanine adducts (11,12) and reverses the cytotoxicity induced by the two types of alkylating agents. Correspondence to: Dr Takahiro Yamauchi, Department of The cytotoxic effects of alkylating agents are limited Hematology and Oncology, Faculty of Medical Sciences, University by a number of factors, including DNA repair (2,13,14). In of Fukui, 23 Shimoaizuki, Matsuoka, Eiheiji, Fukui 910-1193, Japan the present study, the cytotoxic effects of the bifunctional E-mail: [email protected] BCNU and MEL agents, as well as the monofunctional TMZ agent, were evaluated in relation to DNA repair. The Abbreviations: IC50, 50% growth-inhibitory concentration; MMR, mismatch repair; MGMT, O6-methylguanine-DNA methyltransferase; effects were compared in two cultured leukemia cell lines, NER, nucleotide excision repair; BG, O6-benzylguanine; HL-60 and MOLT-4. In addition, the sensitivity of the cells TMZ, temozolomide or 3,4-dihydro-3-methyl-4-oxoimidazo was manipulated by the addition of an MGMT inhibitor, 6 (5,1-d)-as-tetrazine-8-carboxamide; BCNU, carmustine or O -benzylguanine (BG). The extent of the drug cytotox- 1,3-bis(2-chloroethyl)-1-nitrosourea; MEL, melphalan icity was analyzed to determine its correlation with DNA repair, including any associations with MGMT, NER and Key words: DNA repair, temozolomide, carmustine, melphalan, MMR (15,16). 6 O -benzylguanine Our previous study demonstrated the important role of MMR in the exertion of the cytotoxicity of monofunctional agent temozolomide (17). Restored MMR sensitized the 846 ARAI et al: SENSITIZATION OF LEUKEMIC CELLS TO ALKYLATING AGENTS cancer cells to temozolomide. Therefore, the aim of the Table I. Drug sensitivities of the two leukemia cell lines. present study was to evaluate the cytotoxicity of alkylating agents from the viewpoint of MGMT. IC50 (µM) ------------------------------------------------------------- Drugs HL-60 MOLT-4 Materials and methods TMZ 49.0 191.5 Chemicals and reagents. BCNU, MEL and BG (all BCNU 10.0 22.0 purchased from Sigma-Aldrich, St. Louis, MO, USA) were dissolved in 99% ethanol immediately prior to use. TMZ MEL 4.5 1.5 (Schering-Plough KK, Osaka, Japan) was dissolved in 100% TMZ+BG 4.5 169.0 dimethyl sulfoxide immediately prior to use. BCNU+BG 3.0 1.4 MEL+BG 0.3 1.4 Cell culture. Human acute myeloid leukemia cell line, HL-60, and human acute T lymphoblastic leukemia cell line, Cells were incubated with various concentrations of TMZ, BCNU MOLT-4, were used in this study (JCRB Cell Bank, Osaka, or MEL, with or without BG. The IC50 values were then determined using the trypan blue exclusion assay. TMZ, temozolomide; BCNU, Japan). The cells were cultured in RPMI 1640 medium (Life 6 carmustine; MEL, melphalan; BG, O -benzylguanine; IC50, 50% Technologies Japan, Ltd., Tokyo, Japan) in a humidified growth-inhibitory concentration. atmosphere with 5% CO2 at 37˚C. Drug treatment and proliferation assay. To evaluate the growth-inhibitory effect of each agent on the two cell lines, Table II. Sensitization by the addition of BG. the trypan blue exclusion assay was performed (17,18). Briefly, the cells were incubated with various concentra- Ratio of IC50 tions of TMZ, BCNU or MEL (10 nM, 100 nM, 1 µM or ----------------------------------------------------- 10 µM), alone or in combination with BG (10 µM), for 72 h. Drugs HL-60 MOLT-4 Subsequently, the samples were stained with trypan blue TMZ / TMZ+BG 10.9 1.1 (Wako Pure Chemical Industries, Ltd., Osaka, Japan), and the viable cells, which exhibited negative staining, were BCNU / BCNU+BG 3.3 15.7 MEL / MEL+BG 15.0 1.1 counted. The 50% growth-inhibitory concentration (IC50) was the concentration at which 50% of the growth of the Ratios of IC values = (IC value of TMZ, BCNU or MEL treat- untreated cells was inhibited. This value was extrapolated 50 50 ment) / (IC50 value of TMZ, BCNU or MEL treatment in combination from the growth curve drawn for each drug treatment, with with BG). TMZ, temozolomide; BCNU, carmustine; MEL, melphalan; 6 100% considered to be the condition of untreated cells. BG, O -benzylguanine; IC50, 50% growth-inhibitory concentration. Reverse transcription‑quantitative polymerase chain reac‑ tion (RT‑qPCR). The transcript levels of MGMT, ERCC1, hMLH1 and hMSH2 were determined by RT-qPCR using was used for determination of any correlation between two the ABI Prism 7700 sequence detection system (Applied parameters. All statistical analyses were performed using Biosystems Life Technologies, Foster City, CA, USA). Microsoft Excel 2007 (Microsoft Corporation, Redmond, RT-qPCR was performed according to the method of our WA, USA). P<0.05 was considered to indicate a statistically previous study (17). ERCC1 is responsible for incision significant difference. of the damaged DNA strand in the NER pathway, while hMLH1 and hMSH2 are two key factors in the MMR Results response. For MGMT, the sense primer sequence was 5'-TCCCGTTTTCCAGCAAGAGTC-3', and the antisense Growth‑inhibitory effects of the alkylating agents. The sequence was 5'-GGGCTGCTAATTGCTGGTAAGA-3'. growth-inhibitory effects of TMZ, BCNU and MEL were The TaqMan probe DNA sequence was FAM-CCAGACA evaluated in the HL-60 and MOLT-4 cells. Overall, the sensi- GGTGTTATGGAAGCTGCTGAAG-TAMRA (Mitsubishi tivity of the two cell lines to these agents varied; however, Kagaku Bio-Clinical Laboratories, Tokyo, Japan). In addition, treatment with MEL appeared to be the most effective in the primers for ERCC1, hMLH1 and hMSH2 were purchased inhibiting the cell growth (Table I). from Mitsubishi Kagaku Bio-Clinical Laboratories. The absolute standard curve quantitation method was used for Inhibition of MGMT by BG. The cytotoxic effect of alkyl- MGMT and ERCC1, and the relative standard curve quanti- ating agents is generally reduced by DNA repair in cancer tation method was used for hMLH1 and hMSH2. The values cells (3-6). Upon treatment of the HL-60 and MOLT-4 cells of HL-60 cells were set to 1 and relative values were deter- with TMZ, BCNU or MEL in the presence of BG, an MGMT mined for the MOLT-4 cells. inhibitor, the two cell lines were apparently sensitized to all these agents (Table I). However, the extent of sensitization Statistical analyses. Graphs were generated using the varied among the drugs in the two cell lines (Table II; Fig. 1). GraphPad Prism software (version 5.0; GraphPad Software, BG was not found to be cytotoxic to cells in the previous Inc., San Diego, CA, USA). Spearman's rank correlation study (17). ONCOLOGY LETTERS 10: 845-849, 2015 847 A B C Figure 1. Changes in the IC50 values following the addition of BG. The cellular sensitivity to (A) TMZ, (B) BCNU or (C) MEL were determined in the HL-60 and MOLT-4 cells in the presence or absence of BG using the trypan blue exclusion assay. Values are expressed as the mean of at least three independent 6 experiments.
Load more

Recommended publications
  • Use of Fluorescence to Guide Resection Or Biopsy of Primary Brain Tumors and Brain Metastases
    Neurosurg Focus 36 (2):E10, 2014 ©AANS, 2014 Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases *SERGE MARBACHER, M.D., M.SC.,1,5 ELISABETH KLINGER, M.D.,2 LUCIA SCHWYZER, M.D.,1,5 INGEBORG FISCHER, M.D.,3 EDIN NEVZATI, M.D.,1 MICHAEL DIEPERS, M.D.,2,5 ULRICH ROELCKE, M.D.,4,5 ALI-REZA FATHI, M.D.,1,5 DANIEL COLUCCIA, M.D.,1,5 AND JAVIER FANDINO, M.D.1,5 Departments of 1Neurosurgery, 2Neuroradiology, 3Pathology, and 4Neurology, and 5Brain Tumor Center, Kantonsspital Aarau, Aarau, Switzerland Object. The accurate discrimination between tumor and normal tissue is crucial for determining how much to resect and therefore for the clinical outcome of patients with brain tumors. In recent years, guidance with 5-aminolev- ulinic acid (5-ALA)–induced intraoperative fluorescence has proven to be a useful surgical adjunct for gross-total resection of high-grade gliomas. The clinical utility of 5-ALA in resection of brain tumors other than glioblastomas has not yet been established. The authors assessed the frequency of positive 5-ALA fluorescence in a cohort of pa- tients with primary brain tumors and metastases. Methods. The authors conducted a single-center retrospective analysis of 531 patients with intracranial tumors treated by 5-ALA–guided resection or biopsy. They analyzed patient characteristics, preoperative and postoperative liver function test results, intraoperative tumor fluorescence, and histological data. They also screened discharge summaries for clinical adverse effects resulting from the administration of 5-ALA. Intraoperative qualitative 5-ALA fluorescence (none, mild, moderate, and strong) was documented by the surgeon and dichotomized into negative and positive fluorescence.
    [Show full text]
  • Melphalan) for Injection, for Intravenous Use History of Serious Allergic Reaction to Melphalan Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION --------------------DOSAGE FORMS AND STRENGTHS----------------------- These highlights do not include all the information needed to use For Injection: 50 mg per vial, lyophilized powder in a single-dose vial for EVOMELA safely and effectively. See full prescribing information for reconstitution. (3) EVOMELA. ---------------------------CONTRAINDICATIONS---------------------------------- EVOMELA® (melphalan) for injection, for intravenous use History of serious allergic reaction to melphalan Initial U.S. Approval: 1964 WARNING: SEVERE BONE MARROW SUPPRESSION, ---------------------WARNINGS AND PRECAUTIONS-------------------------- HYPERSENSITIVITY, and LEUKEMOGENICITY See full prescribing information for complete boxed warning. • Gastrointestinal toxicity: Nausea, vomiting, diarrhea or oral mucositis may occur; provide supportive care using antiemetic and antidiarrheal • Severe bone marrow suppression with resulting infection or medications as needed. (2.1, 5.2) bleeding may occur. Controlled trials comparing intravenous (IV) • Embryo-fetal toxicity: Can cause fetal harm. Advise of potential risk to melphalan to oral melphalan have shown more myelosuppression fetus and to avoid pregnancy . (5.6, 8.1, 8.3) with the IV formulation. Monitor hematologic laboratory • Infertility: Melphalan may cause ovarian function suppression or testicular parameters. (5.1) suppression. (5.7) • Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation
    [Show full text]
  • UC Irvine UC Irvine Previously Published Works
    UC Irvine UC Irvine Previously Published Works Title ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN Permalink https://escholarship.org/uc/item/2w97d9jv Journal Neuro-Oncology, 20(suppl_6) ISSN 1522-8517 Authors Kong, Xiao-Tang Lai, Albert Carrillo, Jose A et al. Publication Date 2018-11-05 DOI 10.1093/neuonc/noy148.045 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Abstracts 3 dyspnea; grade 2 hemorrhage, non-neutropenic fever; and grade 1 hand- toxicities include: 1 patient with pre-existing vision dysfunction had Grade foot. CONCLUSIONS: Low-dose capecitabine is associated with a modest 4 optic nerve dysfunction; 2 Grade 4 hematologic events and 1 Grade 5 reduction in MDSCs and T-regs and a significant increase in CTLs. Toxicity event(sepsis) due to temozolamide-induced cytopenias. CONCLUSION: has been manageable. Four of 7 evaluable patients have reached 6 months 18F-DOPA-PET -guided dose escalation appears reasonably safe and toler- free of progression. Dose escalation continues. able in patients with high-grade glioma. ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL COMBINATION WITH STANDARD THERAPY FOR UPFRONT OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Downloaded from https://academic.oup.com/neuro-oncology/article/20/suppl_6/vi13/5153917 by University of California, Irvine user on 27 May 2021 METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN Vinay Puduvalli1, Jing Wu2, Ying Yuan3, Terri Armstrong2, Jimin Wu3, Xiao-Tang Kong1, Albert Lai2, Jose A.
    [Show full text]
  • 2016 ASCO TRC102 + Temodar Phase 1 Poster
    Phase I Trial of TRC102 (methoxyamine HCL) in Combination with Temozolomide in Patients with Relapsed Solid Tumors Robert S. Meehan1, Alice P. Chen1, Geraldine Helen O'Sullivan Coyne1, Jerry M. Collins1, Shivaani Kummar1, Larry Anderson1, Kazusa Ishii1, Jennifer Zlott1, 1 1 2 1 1 2 2 1,3 #2556 Larry Rubinstein , Yvonne Horneffer , Lamin Juwara , Woondong Jeong , Naoko Takebe , Robert J. Kinders , Ralph E. Parchment , James H. Doroshow 1Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892 2Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702; 3Center for Cancer Research, NCI, Bethesda, Maryland 20892 Introduction Patient Characteristics Adverse Events Response • Base excision repair (BER), one of the pathways of DNA damage repair, has been implicated in No. of Patients 34 C3D1 chemoresistance. Age (median) 60 Adverse Event Grade 2 Grade 3 Grade 4 Baseline C3D1 Baseline Range 39-78 Neutrophil count decreased 1 3 2 • TRC102 is a small molecule amine that covalently binds to abasic sites generated by BER, Race Platelet count decreased 2 1 2 resulting in DNA strand breaks and apoptosis; therefore, co-adminstraion of TRC102 is Caucasian 24 African American 6 Lymphocyte count decreased 6 5 anticipated to enhance the antitumor activity of temozolomide (TMZ), which methylates DNA Asian 2 Anemia 9 3 1 at N-7 and O-6 positions of guanine. Hispanic 2 Hypophosphatemia 2 2 Tumor Sites • We conducted a phase 1 trial of TRC102 in combination with TMZ to determine the safety, tolerability, GI 11 Fatigue 3 1 and maximum tolerated dose (MTD) of the combination (Clinicaltrials.gov identifier: NCT01851369) H&N 4 Hypophosphatemia 1 Lung 7 Hemolysis 1 1 1 • First enrollment: 7/16/2013.
    [Show full text]
  • In Patients with Metastatic Melanoma Nageatte Ibrahim1,2, Elizabeth I
    Cancer Medicine Open Access ORIGINAL RESEARCH A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma Nageatte Ibrahim1,2, Elizabeth I. Buchbinder1, Scott R. Granter3, Scott J. Rodig3, Anita Giobbie-Hurder4, Carla Becerra1, Argyro Tsiaras1, Evisa Gjini3, David E. Fisher5 & F. Stephen Hodi1 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 2Currently at Merck & Co.,, Kenilworth, New Jersey 3Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts 4Department of Biostatistics & Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 5Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts Keywords Abstract HDAC, immunotherapy, LBH589, melanoma, MITF, panobinostat Epigenetic alterations by histone/protein deacetylases (HDACs) are one of the many mechanisms that cancer cells use to alter gene expression and promote Correspondence growth. HDAC inhibitors have proven to be effective in the treatment of specific Elizabeth I. Buchbinder, Dana-Farber Cancer malignancies, particularly in combination with other anticancer agents. We con- Institute, 450 Brookline Avenue, Boston, ducted a phase I trial of panobinostat in patients with unresectable stage III or 02215, MA. Tel: 617 632 5055; IV melanoma. Patients were treated with oral panobinostat at a dose of 30 mg Fax: 617 632 6727; E-mail: [email protected] daily on Mondays, Wednesdays, and Fridays (Arm A). Three of the six patients on this dose experienced clinically significant thrombocytopenia requiring dose Funding Information interruption. Due to this, a second treatment arm was opened and the dose Novartis Pharmaceuticals Corporation was changed to 30 mg oral panobinostat three times a week every other week provided clinical trial support, additional (Arm B).
    [Show full text]
  • Refractory Multiple Myeloma Patients: a Meta-Analysis and Systematic Review
    OncoTargets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Arsenic trioxide-based therapy in relapsed/ refractory multiple myeloma patients: a meta-analysis and systematic review Xuepeng He Abstract: Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of Kai Yang malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. Peng Chen Although some newly approved drugs (thalidomide, lenalidomide, and bortezomib) demonstrate Bing Liu significant benefit for MM patients with improved survival, all MM patients still relapse. Arsenic Yuan Zhang trioxide (ATO) is the most active single agent in acute promyelocytic leukemia, the antitumor Fang Wang activity of which is partly dependent on the production of reactive oxygen species. Due to its multifaceted effects observed on MM cell lines and primary myeloma cells, Phase I/II trials have Zhi Guo been conducted in heavily pretreated patients with relapsed or refractory MM. Therapy regimens Xiaodong Liu varied dramatically as to the dosage of ATO and monotherapy versus combination therapy with Jinxing Lou For personal use only. other agents available for the treatment of MM. Although ATO-based combination treatment Huiren Chen was well tolerated by most patients, most trials found that ATO has limited effects on MM Department of Hematology, patients. However, since small numbers of patients were randomized to different treatment General Hospital of Beijing arms, trials have not been statistically powered to determine the differences in progression-free Military Area of PLA, Beijing, People’s Republic of China survival and overall survival among the experimental arms.
    [Show full text]
  • Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant
    Author Manuscript Published OnlineFirst on April 1, 2020; DOI: 10.1158/1541-7786.MCR-19-0669 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Targeting NAD+ biosynthesis overcomes panobinostat and bortezomib-induced malignant glioma resistance Esther P. Jane, 1, 2 Daniel R. Premkumar, 1, 2, 3 Swetha Thambireddy, 1 Brian Golbourn, 1 Sameer Agnihotri, 1, 2, 3 Kelsey C. Bertrand, 4 Stephen C. Mack, 4 Max I. Myers, 1 Ansuman Chattopadhyay, 5 D. Lansing Taylor, 6, 7, 8 Mark E. Schurdak, 6, 7, 8 Andrew M. Stern, 7, 8 and Ian F. Pollack 1, 2, 3 Department of Neurosurgery 1, University of Pittsburgh School of Medicine 2, University of Pittsburgh Cancer Institute Brain Tumor Center 3, Texas Children's Hospital, Baylor College of Medicine 4, University of Pittsburgh Molecular Biology Information Service 5, University of Pittsburgh Cancer Institute 6, University of Pittsburgh Drug Discovery Institute 7, Department of Computational and Systems Biology, University of Pittsburgh School of Medicine 8, Pittsburgh, Pennsylvania, U.S.A. Disclosure of Potential Conflict of Interest The authors have declared that no conflict of interest exists. 1 Downloaded from mcr.aacrjournals.org on October 2, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on April 1, 2020; DOI: 10.1158/1541-7786.MCR-19-0669 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Keywords: Panobinostat, bortezomib, synergy, resistance, glioma,
    [Show full text]
  • The Synergic Antitumor Effects of Paclitaxel and Temozolomide Co-Loaded in Mpeg-PLGA Nanoparticles on Glioblastoma Cells
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 15 The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells Yuanyuan Xu1,*, Ming Shen1,*, Yiming Li2, Ying Sun1, Yanwei Teng1, Yi Wang2, Yourong Duan1 1 State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200032, P. R. China 2Department of Ultrasound, Huashan Hospital, School of Medicine, Fudan University, Shanghai 200040, P. R. China *These authors have contributed equally to this work Correspondence to: Yourong Duan, e-mail: [email protected] Yi Wang, e-mail: [email protected] Keywords: nanoparticles, synergy, glioblastoma, paclitaxel, temozolomide Received: November 12, 2015 Accepted: February 20, 2016 Published: March 03, 2016 ABSTRACT To get better chemotherapy efficacy, the optimal synergic effect of Paclitaxel (PTX) and Temozolomide (TMZ) on glioblastoma cells lines was investigated. A dual drug-loaded delivery system based on mPEG-PLGA nanoparticles (NPs) was developed to potentiate chemotherapy efficacy for glioblastoma. PTX/TMZ-NPs were prepared with double emulsification solvent evaporation method and exhibited a relatively uniform diameter of 206.3 ± 14.7 nm. The NPs showed sustained release character. Cytotoxicity assays showed the best synergistic effects were achieved when the weight ratios of PTX to TMZ were 1:5 and 1:100 on U87 and C6 cells, respectively. PTX/TMZ-NPs showed better inhibition effect to U87 and C6 cells than single drug NPs or free drugs mixture. PTX/TMZ-NPs (PTX: TMZ was 1:5(w/w)) significantly inhibited the tumor growth in the subcutaneous U87 mice model.
    [Show full text]
  • Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, And
    ANTICANCER RESEARCH 33: 1989-2000 (2013) Evaluation of Melphalan, Oxaliplatin, and Paclitaxel in Colon, Liver, and Gastric Cancer Cell Lines in a Short-term Exposure Model of Chemosaturation Therapy by Percutaneous Hepatic Perfusion RAJNEESH P. UZGARE, TIMOTHY P. SHEETS and DANIEL S. JOHNSTON Pharmaceutical Research and Development, Delcath Systems, Inc., Queensbury, NY, U.S.A. Abstract. Background: The goal of this study was to candidates for use in the CS-PHP system to treat patients determine whether liver, gastric, or colonic cancer may be with gastric and colonic metastases, and primary cancer of suitable targets for chemosaturation therapy with the liver. percutaneous hepatic perfusion (CS-PHP) and to assess the feasibility of utilizing other cytotoxic agents besides Chemotherapeutic molecules exert beneficial clinical effects melphalan in the CS-PHP system. Materials and Methods: by inhibiting cell growth or by inducing cell death via Forty human cell lines were screened against three cytotoxic apoptosis. They can be divided into several categories based chemotherapeutic agents. Specifically, the dose-dependent on their mechanisms of action. The chemotherapeutic agent effect of melphalan, oxaliplatin, and paclitaxel on melphalan hydrochloride, which has been approved by the proliferation and apoptosis in each cell line was evaluated. US Food and Drug Administration and is used in the These agents were also evaluated for their ability to induce treatment of multiple myeloma and ovarian cancer, is a apoptosis in normal primary human hepatocytes. A high- derivative of nitrogen mustard that acts as a bifunctional dose short-term drug exposure protocol was employed to alkylating agent. Melphalan causes the alkylation of DNA at simulate conditions encountered during CS-PHP.
    [Show full text]
  • Recommendations for the Adjustment of Dosing in Elderly Cancer Patients with Renal Insufficiency
    EUROPEANJOURNALOFCANCER43 (2007) 14– 34 available at www.sciencedirect.com journal homepage: www.ejconline.com Position Paper International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency Stuart M. Lichtmana, Hans Wildiersb, Vincent Launay-Vacherc, Christopher Steerd, Etienne Chatelute, Matti Aaprof,* aMemorial Sloan-Kettering Cancer Centre, New York, USA bUniversity Hospital Gasthuisberg, Leuven, Belgium cHoˆpital Pitie´-Salpeˆtrie`re, Paris, France dMurray Valley Private Hospital, Wodonga, Australia eUniversite´ Paul-Sabatier and Institut Claudius-Regaud, Toulouse, France fDoyen IMO Clinique de Genolier, 1272 Genolier, Switzerland ARTICLE INFO ABSTRACT Article history: A SIOG taskforce was formed to discuss best clinical practice for elderly cancer patients Received 27 October 2006 with renal insufficiency. This manuscript outlines recommended dosing adjustments for Accepted 9 November 2006 cancer drugs in this population according to renal function. Dosing adjustments have been made for drugs in current use which have recommendations in renal insufficiency and the elderly, focusing on drugs which are renally eliminated or are known to be nephrotoxic. Keywords: Recommendations are based on pharmacokinetic and/or pharmacodynamic data where Clinical practice recommendations available. The taskforce recommend that before initiating therapy, some form of geriatric Elderly assessment should be conducted that includes evaluation of comorbidities and polyphar- Cancer macy, hydration status and renal function (using available formulae). Within each drug Renal insufficiency class, it is sensible to use agents which are less likely to be influenced by renal clearance. Creatinine clearance Pharmacokinetic and pharmacodynamic data of anticancer agents in the elderly are Serum creatinine needed in order to maximise efficacy whilst avoiding unacceptable toxicity.
    [Show full text]
  • Targeting Autophagy Augments in Vitro and in Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy
    Author Manuscript Published OnlineFirst on February 2, 2011; DOI: 10.1158/1078-0432.CCR-10-0890 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy Yaozhu Pan1,3, Ying Gao1,3, Liang Chen1,2, Guangxun Gao1, Hongjuan Dong1, Yang Yang1, Baoxia Dong1, Xiequn Chen1 1Department of Hematology, Xijing Hospital, Fourth Military Medical University; Xi’an, People’s Republic of China 2Department of Bioengineering, School of Life Science and Technology, Xi’an Jiaotong University, Xi’an, People’s Republic of China Running head: autophagy and DNA-damaging chemotherapy in MM 3These authors contributed equally to this work. Key words: multiple myeloma; autophagy; apoptosis; DNA damage; xenograft model Corresponding author: Xiequn Chen, Department of Hematology, Xijing Hospital, Fourth Military Medical University, No.17 Changle West Road, Xi’an 710032, China; e-mail: [email protected]; [email protected] 1 Downloaded from clincancerres.aacrjournals.org on September 28, 2021. © 2011 American Association for Cancer Research. Author Manuscript Published OnlineFirst on February 2, 2011; DOI: 10.1158/1078-0432.CCR-10-0890 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational Relavance Multiple myeloma (MM) is a hematologic malignancy resulting from a clonal proliferation of plasma cells in the bone marrow. Although there have been major advances in the treatment of MM in recent years, it remains incurable mostly because of the development of drug resistance. Herein, we demonstrates that DNA-damaging agents (such as doxorubicin and melphalan) induced autophagy as a prosurvival mechanism in MM cells by engaging Bcl-2/Beclin1/Class III phosphatidylinositol 3-kinase complex.
    [Show full text]
  • High-Dose Mitoxantrone + Melphalan (MITO/L-PAM)
    Leukemia (2001) 15, 256–263 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity C Tarella1, F Zallio1, D Caracciolo1, A Cuttica1, P Corradini1,2, P Gavarotti1, M Ladetto1, V Podio3, A Sargiotto4, G Rossi5, AM Gianni6 and A Pileri1 1Dipartimento di Medicina e Oncologia Sperimentale, Divisione Universitaria di Ematologia; Serv. 3Univ. e 4Osped di Medicina Nucleare; 5Divisione Universitaria di Radioterapia-Azienda Ospedaliera S Giovanni Battista di Torino, Torino; and 6Unita` Trapianto Midollo, Ist Naz. Tumori, Milano, Italy Hematological and extrahematological toxicity of high-dose The ease deriving from the excellent tolerability of PBPC (hd) mitoxantrone (MITO) and melphalan (L-PAM) as condition- procedures probably slowed down the efforts aimed to look ing regimen prior to peripheral blood progenitor cell (PBPC) autograft was evaluated in 113 lymphoma patients (87 at dis- for innovative and possibly more effective conditioning regi- ease onset). Autograft was the final part of a hd-sequential mens. In fact, most autograft programs employed nowadays (HDS) chemotherapy program, including a debulkying phase are based on conditioning regimens designed several years (1–2 APO ± 2 DHAP courses) and then sequential adminis- ago, such as TBI + cyclophosphamide (CY), or regimens con- tration of hd-cyclophosphamide, methotrexate (or Ara-C) and taining nitrosurea or melphalan (L-PAM), such as BEAM, CBV etoposide, at 10 to 30 day intervals. Autograft phase included: or BEAC.17–21 Looking for a better conditioning regimen, one (1) hd-MITO, given at 60 mg/m2 on day −5; (2) hd-L-PAM, given at 180 mg/m2 on day −2; (3) PBPC autograft, with a median of should not only consider the antitumor activity of a given drug 11 × 106 CD341/kg, or 70 × 104 CFU-GM/kg, on day 0.
    [Show full text]